{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:55Z","timestamp":1791206395585,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.vaccine.2010.07.063","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T09:03:26Z","timestamp":1280912606000},"page":"6581-6587","source":"Crossref","is-referenced-by-count":70,"title":["A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis"],"prefix":"10.1016","volume":"28","author":[{"given":"Evaldo","family":"Nascimento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios F.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edva P.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Campos-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana P.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Y.","family":"Bogatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel O.","family":"Pine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen D.","family":"Cowgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco M.","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"September (10)","key":"10.1016\/j.vaccine.2010.07.063_bib0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra064142","article-title":"Control of neglected tropical diseases","volume":"357","author":"Hotez","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.07.063_bib0010","series-title":"Hunter's tropical medicine and emerging tropical diseases","first-page":"665","article-title":"Leishmaniasis","author":"Magill","year":"2000"},{"issue":"March\u2013April (2)","key":"10.1016\/j.vaccine.2010.07.063_bib0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clindermatol.2006.05.008","article-title":"Cutaneous leishmaniasis","volume":"25","author":"Bailey","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.vaccine.2010.07.063_bib0020","series-title":"Manual de Controle da Leishmaniose Tegumentar Americana","year":"2000"},{"issue":"1","key":"10.1016\/j.vaccine.2010.07.063_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jcla.20291","article-title":"Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment","volume":"23","author":"Reis","year":"2009","journal-title":"J Clin Lab Anal"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2010.07.063_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Micro Inf Dis"},{"key":"10.1016\/j.vaccine.2010.07.063_bib0035","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ije\/15.4.572","article-title":"Controlled field trial of vaccines against new world cutaneious leishmaniasis","volume":"15","author":"Antunes","year":"1986","journal-title":"Int J Epidemiol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2010.07.063_bib0040","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"issue":"October (20)","key":"10.1016\/j.vaccine.2010.07.063_bib0045","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"September (27\u201328)","key":"10.1016\/j.vaccine.2010.07.063_bib0050","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2010.07.063_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-4362.2002.01336.x","article-title":"Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial","volume":"41","author":"Machado-Pinto","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.vaccine.2010.07.063_bib0060","unstructured":"ICSSC. Monitoring and Reporting Adverse Events: Appendix VII www Resource Links. 2003 [updated February 6, 2003; cited 2009 April 6]; Available from: http:\/\/www.icssc.org\/Documents\/Resources\/AEManual2003AppendicesFebruary_06_2003%20final.pdf [accessed 06.04.2009]."},{"key":"10.1016\/j.vaccine.2010.07.063_bib0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.vaccine.2009.10.045","article-title":"Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis","volume":"28","author":"Velez","year":"2010","journal-title":"Vaccine"},{"issue":"November (9)","key":"10.1016\/j.vaccine.2010.07.063_bib0070","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"},{"issue":"August (5)","key":"10.1016\/j.vaccine.2010.07.063_bib0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1590\/S0074-02762007005000069","article-title":"T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis","volume":"102","author":"Bittar","year":"2007","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"April (19)","key":"10.1016\/j.vaccine.2010.07.063_bib0080","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine LEISH-111F+MPL-SE","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.07.063_bib0085","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1000238","article-title":"Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis","volume":"185","author":"Raman","year":"2010","journal-title":"J Immunol"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2010.07.063_bib0090","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1128\/IAI.69.9.5270-5277.2001","article-title":"Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein","volume":"69","author":"Borges","year":"2001","journal-title":"Infect Immun"},{"issue":"10 Suppl.","key":"10.1016\/j.vaccine.2010.07.063_bib0095","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0966-842X(02)02426-5","article-title":"Taking toll: lipid A mimetics as adjuvants and immunomodulators","volume":"10","author":"Persing","year":"2002","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2010.07.063_bib0100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/bmj.1.2671.540","article-title":"The curative value of Leishmania culture \u201cvaccine\u201d in oriental sore","volume":"1","author":"Row","year":"1912","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2010.07.063_bib0105","first-page":"297","article-title":"Vaccinotherapy in cutaneous leishmaniasis","volume":"40","author":"Dubovsky","year":"1943","journal-title":"Trop Dis Bull"},{"issue":"February (8530)","key":"10.1016\/j.vaccine.2010.07.063_bib0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(87)90116-4","article-title":"Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis","volume":"1","author":"Convit","year":"1987","journal-title":"Lancet"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2010.07.063_bib0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/infdis\/160.1.104","article-title":"Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis","volume":"160","author":"Convit","year":"1989","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2010.07.063_bib0120","first-page":"232","article-title":"Desarrollo de Inmunoterapia de la leishmaniasis Cutanea Americana en el Institutode Biomedicina","volume":"104","author":"Convit","year":"1996","journal-title":"Gaceta Medica de Caracas"},{"issue":"December (1\u20133)","key":"10.1016\/j.vaccine.2010.07.063_bib0125","first-page":"159","article-title":"Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil","volume":"34","author":"Mayrink","year":"1992","journal-title":"Parassitologia"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2010.07.063_bib0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0738-081X(96)00040-5","article-title":"Vaccine for prophylaxis and immunotherapy, Brazil","volume":"14","author":"Genaro","year":"1996","journal-title":"Clin Dermatol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10010741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10010741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T02:23:57Z","timestamp":1544322237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10010741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":26,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0264410X10010741"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.07.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}